Organisation paid for research Program year 2025 Source: CMS Open Payments

Virginia Commonwealth University

Neither a doctor nor a teaching hospital

Research payments

$28,170,110

3,636 payments

Through program year 2025, Virginia Commonwealth University is reported as receiving $28,170,110 in research payments, across 3,636 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,782,991 611
2024 Research $3,405,563 725
2023 Research $3,113,310 355
2022 Research $4,682,551 390
2021 Research $4,343,032 520
2020 Research $4,631,426 526
2019 Research $3,211,238 509

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $4,602,732 205 payments
  2. Gilead Sciences, Inc. $2,261,003 189 payments
  3. Deciphera Pharmaceuticals Inc. $2,058,288 158 payments
  4. Pfizer Inc. $1,150,361 172 payments
  5. Intercept Pharmaceuticals, Inc. $782,411 149 payments
  6. Boston Scientific Corporation $770,700 212 payments
  7. Vertex Pharmaceuticals Incorporated $731,713 3 payments
  8. NS Pharma, Inc. $678,668 133 payments
  9. Kyowa Kirin, Inc. $657,289 15 payments
  10. Janssen Research & Development, LLC $643,559 68 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Safety Tolerability and PK Study of Dcc-2618 in Patients With Advanced Malignancies $1,590,135 101 payments
  2. T cell Immune Checkpoint Inhibition Plus Hypomethylation for Breast Cancer a Neoadjuvant Window Trial $1,194,729 4 payments
  3. A Phase 4, single-arm, open-label clinical study of pembrolizumab MK-3475 to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent,metastatic head and neck squamous cell carcinoma KEYNOTE-B10 $1,064,236 14 payments
  4. A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer KEYNOTE-A18 , ENGOT-cx11,GOG-3047 $781,767 12 payments
  5. END DM1 Natural History Study COnsortium, Access to data, inveustgator meetings and bionmarker tissue samples $731,462 2 payments
  6. Istradefylline for Parkinson disease dementia $657,289 15 payments
  7. In-Dure Glove $517,153 7 payments
  8. Investigator Sponsored Research $511,253 9 payments
  9. A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) $479,538 6 payments
  10. The Simple Study in Coronavirus, Severe Subjects $416,568 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $72,789 9 payments
  2. Other $67,448 6 payments
  3. Professional salary support $38,850 10 payments
  4. Non-patient care $29,571 6 payments
  5. Overhead $12,609 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record